NCT07020702 ElectroPhySiological Characterization Of the Arrhythmia Substrate for Sudden Cardiac Death PrEdiction
| NCT ID | NCT07020702 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Ventricular Arrhythmia |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2023-06-12 |
| Primary Completion | 2030-09-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 210 participants in total. It began in 2023-06-12 with a primary completion date of 2030-09-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
EP-SCOPE is a prospective, multicentric, non-randomized pilot study that aims to estimate the risk of life-threatening ventricular arrhythmia through use of advanced electrophysiological studies in patients with ischemic or non-ischemic cardiomyopathy with left ventricular ejection fraction (LVEF) \<50% and risk factors of ventricular arrhythmia, otherwise not considered for implantation of an implantable cardioverter defibrillator (ICD). The objective is to assess the effectiveness of a risk stratification strategy based on detailed electrophysiological exploration of the left ventricle and programmed ventricular stimulation.
Eligibility Criteria
Inclusion Criteria: * Patient with cardiomyopathy with 35%\<LVEF\<50% and at least one risk factor * Patients with cardiomyopathy with LVEF≤35% and an indication for cardiac resynchronisation Exclusion Criteria: * Patients who are minors or aged 80 or over * Patients with unstable coronary artery disease * Myocardial infarction less than 40 days old * Coronary revascularisation \<90 days * Patients with intracardiac thrombus * Patients with a mechanical heart valve * Patient implanted with an automatic defibrillator * Patient life expectancy \<1 year * Pregnant or breast-feeding women * Anti-arrhythmic drugs other than beta-blockers and amiodarone
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07020702 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Ventricular Arrhythmia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07020702 currently recruiting?
Yes, NCT07020702 is actively recruiting participants. Contact the research team at sylvain.ploux@chu-bordeaux.fr for enrollment information.
Where is the NCT07020702 trial being conducted?
This trial is being conducted at Clermont-Ferrand, France, Pessac, France, Saint-Etienne, France.
Who is sponsoring the NCT07020702 clinical trial?
NCT07020702 is sponsored by University Hospital, Bordeaux. The trial plans to enroll 210 participants.